These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31616133)

  • 1. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
    Yanbeiy ZA; Hansen KE
    Drug Des Devel Ther; 2019; 13():2843-2852. PubMed ID: 31616133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
    Jiang L; Dong J; Wei J; Liu L
    BMC Musculoskelet Disord; 2022 Nov; 23(1):1027. PubMed ID: 36447169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
    Yuan C; Liang Y; Zhu K; Xie W
    J Orthop Surg Res; 2023 Jun; 18(1):447. PubMed ID: 37349750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
    Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
    Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
    Iseri K; Iyoda M; Watanabe M; Matsumoto K; Sanada D; Inoue T; Tachibana S; Shibata T
    PLoS One; 2018; 13(3):e0193846. PubMed ID: 29543887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
    Saag KG; Wagman RB; Geusens P; Adachi JD; Messina OD; Emkey R; Chapurlat R; Wang A; Pannacciulli N; Lems WF
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):445-454. PubMed ID: 29631782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials.
    Liu Z; Zhang M; Shen Z; Ke J; Zhang D; Yin F
    PLoS One; 2020; 15(12):e0243851. PubMed ID: 33326444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials.
    Dong B; Zhou Y; Wang J; Li C; Fu Z; Huang Y; Wang Y; Xu L
    Horm Metab Res; 2023 Apr; 55(4):236-244. PubMed ID: 36652960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
    Hayakawa N; Suzuki A
    Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
    Lyu H; Jundi B; Xu C; Tedeschi SK; Yoshida K; Zhao S; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 May; 104(5):1753-1765. PubMed ID: 30535289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for glucocorticoid-induced osteoporosis.
    Chiodini I; Merlotti D; Falchetti A; Gennari L
    Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-Year Teriparatide Followed by Denosumab
    Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
    Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
    Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
    Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis.
    Dong L; Jiang L; Xu Z; Zhang X
    Front Pharmacol; 2024; 15():1336075. PubMed ID: 38313307
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.
    Okubo N; Matsui S; Matsumoto T; Sugimoto T; Hosoi T; Osakabe T; Watanabe K; Takami H; Shiraki M; Nakamura T
    Calcif Tissue Int; 2020 Dec; 107(6):559-566. PubMed ID: 32839843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.
    Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP
    Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab in the treatment of glucocorticoid-induced osteoporosis.
    Coskun Benlidayi I
    Rheumatol Int; 2018 Nov; 38(11):1975-1984. PubMed ID: 30019224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.